Banco Santander S.A. Sells 502 Shares of Edwards Lifesciences Co. (NYSE:EW)

Banco Santander S.A. decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,274 shares of the medical research company’s stock after selling 502 shares during the period. Banco Santander S.A.’s holdings in Edwards Lifesciences were worth $1,602,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in EW. First Community Trust NA bought a new stake in shares of Edwards Lifesciences during the second quarter worth $29,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Webster Bank N. A. bought a new stake in Edwards Lifesciences in the 2nd quarter worth about $39,000. Finally, Peoples Bank KS purchased a new stake in Edwards Lifesciences during the third quarter worth about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,000 shares of company stock valued at $2,657,000. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.2 %

Shares of NYSE:EW opened at $70.49 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $41.58 billion, a price-to-earnings ratio of 10.17, a PEG ratio of 3.95 and a beta of 1.12. The stock’s 50-day simple moving average is $67.70 and its two-hundred day simple moving average is $75.73. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.59 earnings per share. Analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on EW shares. Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Truist Financial decreased their target price on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Barclays reduced their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Finally, Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.